Skip to menu Skip to content Skip to footer
Dr

Danushka Wijesundara

Email: 
Phone: 
+61 7 344 32597

Overview

Background

I completed my Bachelor of Biotechnology with First Class Honours at the Australian National University (ANU) during 2008. During my honours, I became interested in understanding ways to best harness the immune system in combating viral infections. Consequently, I embarked on a PhD project at The John Curtin School of Medical Research, ANU during 2010 to understand ways to improve the efficacy of genetically modified and safe pox viral vaccines to target human immunodeficiency virus (HIV). I completed this project during 2014 and worked as a an Early Career Fellow (sponsored by The Hospital Research Foundation) at the University of Adelaide to develop safe and effective vaccines against HIV, hepatitis C virus (HCV) and Zika virus. I joined the The University of Queensland during May, 2019 to develop a 'Rapid Response Vaccine Pipeline' (sponsored by The Coalition for Epidemic Preparedness Innovations (CEPI)) to target emerging/re-emerging viral infections using a prioprietary 'Molecular Clamp' vaccine technology. My career objective is to develop vaccines that can be effective in protective humans against viral infections.

Availability

Dr Danushka Wijesundara is:
Available for supervision

Qualifications

  • Doctor of Philosophy, Australian National University

Research impacts

As an early career researcher (PhD awarded in 2014), I have published 30 peer-reviewed manuscripts, been the recipient of 16 competitive academic awards, supervised several higher degree research students and presented mainly as a speaker in 18 national/international conferences. Three of the academic awards were presented to me in consecutive Australian Centre for HIV and hepatitis virology (ACH2) conferences (2015, 2017 and 2018), which is the premier national meeting for HIV and hepatitis basic and translational research in Australia. I have also been a chief investigator in 8 awarded grants and am the recipient of an Early Career Fellowship from The Hospital Research Foundation. I received one of these grants as the Principal Investigator during 2019 from the Channel 7 Children's Research Foundation (co-sponsored by The Hospital Research Foundation). Recently, Dr. Grubor-Bauk, Prof. Gowans and I have received a provisional patent for a highly protective vaccine that target the non-structural protein 1 (NS1) of Zika virus which received the support of a Commercial Acceleration Scheme Grant (The University of Adelaide) this year.

I was invited to speak in 4 departmental seminars (2 in the USA: Wadsworth Center, New York and Louisiana State University, New Orleans), have delivered a lecture at The Albany Pharmacy College, New York, USA, and presented to the community in numerous occasions (e.g. Science in the Pub, Science Alive, radio interviews with Coast FM (Adelaide),etc.) regarding scientific endeavours and controversies. I have reviewed manuscripts for publication in 13 peer-review journals (e.g. Scientific Reports, Frontiers in Immunology, Immunology and Cell Biology, etc.) and been an external assessor for 7 NHMRC project grant applications. I have also been fortunate enough to collaborate with the industry (e.g. Imaxio and MuPharma) and many prestigious academics (e.g. Prof. Andrew Lloyd (The University of New South Wales), Prof. Dan Barouch (Harvard Medical School) and Prof. Chris Parish (The Australian National University).

I have actively contributed to research and improving the community's understanding about vaccine research. I wish to continue on this trajectory and contribute productively to science and the community as an employee at UQ.

Works

Search Professor Danushka Wijesundara’s works on UQ eSpace

14 works between 2020 and 2024

1 - 14 of 14 works

2024

Journal Article

Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein

McMillan, Christopher L. D., Wijesundara, Danushka K., Choo, Jovin J. Y., Amarilla, Alberto A., Modhiran, Naphak, Fernando, Germain J. P., Khromykh, Alexander A., Watterson, Daniel, Young, Paul R. and Muller, David A. (2024). Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein. Journal of General Virology, 105 (1) 001947, 1-6. doi: 10.1099/jgv.0.001947

Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein

2023

Journal Article

Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine

Wijesundara, Danushka K., Yeow, Arthur, McMillan, Christopher L. D., Choo, Jovin J. Y., Todorovic, Aleksandra, Mekonnen, Zelalem A., Masavuli, Makutiro G., Young, Paul R., Gowans, Eric J., Grubor-Bauk, Branka and Muller, David A. (2023). Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine. Molecular Therapy Nucleic Acids, 34 102056, 102056. doi: 10.1016/j.omtn.2023.102056

Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine

2023

Journal Article

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R. and Munro, Trent P. (2023). Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial. eBioMedicine, 97 104842, 104842. doi: 10.1016/j.ebiom.2023.104842

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

2023

Journal Article

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein

Albornoz, Eduardo A., Amarilla, Alberto A., Modhiran, Naphak, Parker, Sandra, Li, Xaria X., Wijesundara, Danushka K., Aguado, Julio, Zamora, Adriana Pliego, McMillan, Christopher L. D., Liang, Benjamin, Peng, Nias Y. G., Sng, Julian D. J., Saima, Fatema Tuj, Fung, Jenny N., Lee, John D., Paramitha, Devina, Parry, Rhys, Avumegah, Michael S., Isaacs, Ariel, Lo, Martin W., Miranda-Chacon, Zaray, Bradshaw, Daniella, Salinas-Rebolledo, Constanza, Rajapakse, Niwanthi W., Wolvetang, Ernst J., Munro, Trent P., Rojas-Fernandez, Alejandro, Young, Paul R., Stacey, Katryn J. ... Woodruff, Trent M. (2023). SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Molecular Psychiatry, 28 (7), 2878-2893. doi: 10.1038/s41380-022-01831-0

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein

2022

Journal Article

LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza

Williams, Clare M., Roy, Sreeja, Sun, Wei, Furuya, Andrea M., Wijesundara, Danushka K. and Furuya, Yoichi (2022). LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza. Clinical and Translational Immunology, 11 (3) e1381. doi: 10.1002/cti2.1381

LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza

2021

Journal Article

Fear of influenza resurgence amid covid-19 pandemic: need for effective flu vaccine still exists

Wijesundara, Danushka K., Williams, Clare, Sun, Wei, Furuya, Andrea Marias and Furuya, Yoichi (2021). Fear of influenza resurgence amid covid-19 pandemic: need for effective flu vaccine still exists. Vaccines, 9 (10) 1198, 1198. doi: 10.3390/VACCINES9101198

Fear of influenza resurgence amid covid-19 pandemic: need for effective flu vaccine still exists

2021

Journal Article

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Chappell, Keith J., Mordant, Francesca L., Li, Zheyi, Wijesundara, Danushka K., Ellenberg, Paula, Lackenby, Julia A., Cheung, Stacey T. M., Modhiran, Naphak, Avumegah, Michael S., Henderson, Christina L., Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H. O., Marrero-Hernandez, Sara, Selva, Kevin J., Chung, Amy W., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D., Hogarth, P Mark, Kedzierska, Katherine ... Munro, Trent P. (2021). Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 21 (10), 1383-1394. doi: 10.1016/S1473-3099(21)00200-0

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

2021

Journal Article

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

Watterson, Daniel, Wijesundara, Danushka K., Modhiran, Naphak, Mordant, Francesca L., Li, Zheyi, Avumegah, Michael S., McMillan, Christopher L. D., Lackenby, Julia, Guilfoyle, Kate, van Amerongen, Geert, Stittelaar, Koert, Cheung, Stacey T. M., Bibby, Summa, Daleris, Mallory, Hoger, Kym, Gillard, Marianne, Radunz, Eve, Jones, Martina L., Hughes, Karen, Hughes, Ben, Goh, Justin, Edwards, David, Scoble, Judith, Pearce, Lesley, Kowalczyk, Lukasz, Phan, Tram, La, Mylinh, Lu, Louis, Pham, Tam ... Chappell, Keith J. (2021). Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clinical & Translational Immunology, 10 (4) e1269, e1269. doi: 10.1002/cti2.1269

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

2021

Journal Article

Adjuvant selection for influenza and RSV prefusion subunit vaccines

Isaacs, Ariel, Li, Zheyi, Cheung, Stacey T. M., Wijesundara, Danushka K., McMillan, Christopher L. D., Modhiran, Naphak, Young, Paul R., Ranasinghe, Charani, Watterson, Daniel and Chappell, Keith J. (2021). Adjuvant selection for influenza and RSV prefusion subunit vaccines. Vaccines, 9 (2) 71, 1-14. doi: 10.3390/vaccines9020071

Adjuvant selection for influenza and RSV prefusion subunit vaccines

2020

Journal Article

Impact of pre-existing immunity to influenza on live-attenuated influenza vaccine (Laiv) immunogenicity

Roy, Sreeja, Williams, Clare M., Wijesundara, Danushka K. and Furuya, Yoichi (2020). Impact of pre-existing immunity to influenza on live-attenuated influenza vaccine (Laiv) immunogenicity. Vaccines, 8 (4) 683, 1-13. doi: 10.3390/vaccines8040683

Impact of pre-existing immunity to influenza on live-attenuated influenza vaccine (Laiv) immunogenicity

2020

Journal Article

Rapid response subunit vaccine design in the absence of structural information

Wijesundara, Danushka K., Avumegah, Michael S., Lackenby, Julia, Modhiran, Naphak, Isaacs, Ariel, Young, Paul R., Watterson, Daniel and Chappell, Keith J. (2020). Rapid response subunit vaccine design in the absence of structural information. Frontiers in Immunology, 11 592370, 592370. doi: 10.3389/fimmu.2020.592370

Rapid response subunit vaccine design in the absence of structural information

2020

Journal Article

Immunological memory in imiquimod-induced murine model of psoriasiform dermatitis

Fenix, Kevin, Wijesundara, Danushka K., Cowin, Allison J., Grubor-Bauk, Branka and Kopecki, Zlatko (2020). Immunological memory in imiquimod-induced murine model of psoriasiform dermatitis. International Journal of Molecular Sciences, 21 (19) 7228, 1-13. doi: 10.3390/ijms21197228

Immunological memory in imiquimod-induced murine model of psoriasiform dermatitis

2020

Journal Article

Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity

Roy, Sreeja, Williams, Clare M., Pardo, Julian, Wijesundara, Danushka K. and Furuya, Yoichi (2020). Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity. Vaccines, 8 (3) 459, 1-6. doi: 10.3390/vaccines8030459

Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity

2020

Journal Article

Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus

Gummow, Jason, Masavuli, Makutiro G., Mekonnen, Zelalem A., Li, Yanrui, Wijesundara, Danushka K., Shrestha, Ashish C., Voskoboinik, Ilia, Gowans, Eric J. and Grubor-Bauk, Branka (2020). Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus. Vaccines, 8 (1) 53, 1-15. doi: 10.3390/vaccines8010053

Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus

Funding

Past funding

  • 2021 - 2022
    Molecular Clamp Stabilised HTLV-1 Envelope Glycoprotein for Vaccination and Immunotherapy
    Australian Centre for HIV and Hepatitis Virology Research (ACH2)
    Open grant

Supervision

Availability

Dr Danushka Wijesundara is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Structural and functional characterization of bat antiviral antibodies

    Associate Advisor

    Other advisors: Professor Daniel Watterson

  • Doctor Philosophy

    Unpicking the molecular mechanisms of vaccination using a high-density microarray patch

    Associate Advisor

    Other advisors: Associate Professor David Muller

Media

Enquiries

For media enquiries about Dr Danushka Wijesundara's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au